• Home
  • Articles
  • COVID-19
  • News
    • Biotech News – Featured
    • Biotech News
    • BioGadgets
  • Interviews
    • Interviews – Academia
    • Interviews – Industry
  • Issues
  • Subscribe
  • Board
  • Advertise
Facebook Twitter Instagram
Trending
  • BioAsia 2023 to be held in February 24-26 in Telangana, India
  • Praj Industries and ESIIC partner to further bioeconomy in Egypt
  • Who is The Real Anthony Fauci? A true Doctor, liar, pharma profiteer or a totalitarian?
  • Guestorial: MALNUTRITION ACCELERATES THE METABOLIC AGE
  • Event: Australia’s biggest week in biotech kicks off in Perth
  • $3 trillion growth reported for biotech sector in USA
  • Event : FABA’s Whale Tank Event – “Venture Capital – Biotech Start-up Connect”
  • Vaccination, Rising Deaths, And The False Narrative
Biotech Express Magazine
  • Home
  • Articles
  • COVID-19
  • News
    • Biotech News – Featured
    • Biotech News
    • BioGadgets
  • Interviews
    1. Interviews – Academia
    2. Interviews – Industry
    Featured
    January 16, 20211

    Interview – Prof Rajeev K Varshney “The Youngest Indian Scientist (47)” who achieved an h-index of 100 recently

    Recent
    July 26, 2022

    We are making best hygiene solutions through Biotech applications: Dr Rachna Dave, founder MicroGO

    March 30, 2022

    Interview- Bioenergy: India’s Ministry of New and Renewable Energy started almost four decades ago…but did not catch up…, Professor Ashok Pandey

    January 24, 2022

    Interview: Prof Kailash Chander Bansal, Secretary, National Academy of Agricultural Sciences (NAAS), India

  • Issues
  • Subscribe
  • Board
  • Advertise
Biotech Express Magazine
You are at:Home»Articles»What are the errors in COVID-19 vaccine trial? Astrazeneca, Pfizer and Bharat Biotech

What are the errors in COVID-19 vaccine trial? Astrazeneca, Pfizer and Bharat Biotech

0
By Biotech Express on December 8, 2020 Articles, BioControversial, SARS- CoV2 & COVID-19 Updates

Pharmaceutical giant AstraZeneca and the University of Oxford released positive results about their covid-19 vaccine being the frontrunner, claiming that it was on average 70 per cent effective, and could reach 90 per cent efficacy depending on dosing. But Researchers have raised several questions over the findings.

During the AstraZeneca and the University of Oxford’s clinical trials, some participants were mistakenly given half a dose rather than a full dose in their first round of shots, according to BBC News. Still, the trial continued and the researchers discovered those given the weaker dosage produced a better immune response. The results of the UK trial were published in The Lancet, but the full, combined results have only been revealed in a press release which didn’t include detailed numbers. The University of Oxford said that full results would be submitted to a journal. On Thursday, AstraZeneca announced plans for a new, global trial. According to Mark Toshner, a clinical trials doctor at the University of Cambridge, there have been reports, now confirmed by AstraZeneca, that the people in the half-dose subgroup were younger on average than the participants as a whole, which suggests that the 90 per cent figure may prove too high. Vaccines generally work better in younger people, says Hunter. Neither AstraZeneca nor Oxford released full details of the age profiles of the volunteers in both trials except to say that all were 18 or over. Another wrinkle is that the volunteers were all healthy or had “stable underlying medical conditions”. That may mean that the results don’t reflect how the vaccine will perform among vulnerable groups such as people with serious health problems.

Astrazeneca’s vaccine also got noticed for wrong reason when a volunteer in the Oxford University ‘Covishield’ COVID-19 vaccine trial flagged a serious medical condition called ‘acute neurological encephalopathy’ ten days after he was given the first dose on 1 October. The volunteer reported having had ‘memory loss, ability to reason and concentrate and personality change’, all of which are considered serious neurological and psychological symptoms. He went on to sue SII (which is conducting the trial along with the ICMR) for a compensation of Rs 5 crore. In response, SII filed a Rs 100 crore lawsuit against him for defamation.

On 9th November, Pfizer and BioNTech said in the press release that they had identified 94 cases of COVID-19 among 43,538 trial participants. The companies did not indicate how many of those cases were in the placebo group or among those who got the vaccine. But they said that the split of cases between the groups suggested that the vaccine was more than 90% effective at preventing disease, when measured at least one week after trial participants had received a second vaccine dose 3 weeks after the first. Eric Topol, a cardiologist and director of the Scripps Research Translational Institute in La Jolla, California said What’s missing, are details about the nature of the infections the vaccine can protect against — whether they are mostly mild cases of COVID-19 or also include significant numbers of moderate and severe cases and whether the vaccine can prevent people who show no or only very mild symptoms of COVID-19. Another missing detail is how well the vaccine works in different groups of trial participants. One key unanswered question is how long the vaccine’s effectiveness will last.

Recently questions have been raised on Bharat Biotech’s COVAXIN too when Haryana health minister, Anil Vij, who was given a trial dose of corona vaccine, Covaxin, has been tested positive for the Covid-19. On November 20, he was administered a dose of Covaxin at a hospital in Ambala, as part of its third phase trial, according to his twitter post.

 

Read More in December issue.

Source:

1. https://www.newscientist.com/article/2261092-do-oxford-astrazeneca-covid-19-vaccine-results-stand-up-to-scrutiny/

2. https://edition.cnn.com/2020/11/23/health/astrazeneca-vaccine-data-questions/index.html

3. https://www.nature.com/articles/d41586-020-03166-8

4. https://timesofindia.indiatimes.com/city/chandigarh/haryana-health-minister-anil-vij-who-took-trial-shot-of-bharat-biotechs-vaccine-tests-positive-for-covid-19/articleshow/79578170.cms

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Biotech Express
  • Website
  • Facebook
  • Twitter
  • LinkedIn

ISSN: 2454-6968 | Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports, Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology, Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurosciences, Genetics, Medical Sciences, BioPharma etc.

Related Posts

Who is The Real Anthony Fauci? A true Doctor, liar, pharma profiteer or a totalitarian?

Guestorial: MALNUTRITION ACCELERATES THE METABOLIC AGE

Event : FABA’s Whale Tank Event – “Venture Capital – Biotech Start-up Connect”

Leave A Reply Cancel Reply

Current Issue – October 2022
Upcoming Event

                   VIEW SUBSCRIPTION PLANS

JOBS/NOTIFICATIONS

   

         CLICK HERE FOR RECENT NOTICES

Recent Posts
  • BioAsia 2023 to be held in February 24-26 in Telangana, India January 10, 2023
  • Praj Industries and ESIIC partner to further bioeconomy in Egypt November 10, 2022
  • Who is The Real Anthony Fauci? A true Doctor, liar, pharma profiteer or a totalitarian? November 1, 2022
  • Guestorial: MALNUTRITION ACCELERATES THE METABOLIC AGE October 31, 2022
  • Event: Australia’s biggest week in biotech kicks off in Perth October 26, 2022
  • $3 trillion growth reported for biotech sector in USA October 25, 2022
  • Event : FABA’s Whale Tank Event – “Venture Capital – Biotech Start-up Connect” September 21, 2022
  • Vaccination, Rising Deaths, And The False Narrative September 20, 2022
  • Guestorial: Genome Mapping Techniques and its Application in Aquaculture September 19, 2022
  • Bombay HC Issues Notice To Bill Gates, Serum Institute, DGCI, Others Over Plea On Alleged ‘Vaccine Death’ September 5, 2022
  • Deaths due Covid-19 vaccines should be compensated by vaccine makers: Expert hope on Kerala HC remark August 21, 2022
  • Maker of Dolo-650, pandemic’s ‘magic pill’, faces income tax searches and PIL petitions August 20, 2022
  • Anthony Fauci, Controversial US Top-doc FINALLY, To Retire By Year-end August 20, 2022
  • SII’s Cervevac: The new DCGI approved vaccine without published clinical trial results August 20, 2022
  • Pitch your Start-up to National/International Venture Capitalists – first ever opportunity provided to Bio-Start-ups by FABA August 19, 2022
  • India’s Clinical Trial Registry might disappear soon and so the history of pharma record August 19, 2022
  • Nearly Half of Pregnant Women in Pfizer Trial Miscarried August 10, 2022
  • Researchers develop Cellulose shoes made by bacteria August 9, 2022
  • Biocon Sdn. Bhd. Enters Malaysia Book of Records as the First & the Largest Integrated Insulin Manufacturing Facility August 5, 2022
  • CBI Arrests of CDSCO officials, a Biocon official & Intermediaries in an alleged bribery case exposed Corruption in Govt and Pharma sector July 27, 2022
  • We are making best hygiene solutions through Biotech applications: Dr Rachna Dave, founder MicroGO July 26, 2022
  • EVENT HIGHLIGHTS: Genome editing as a novel technology for sustainable development July 24, 2022
  • US Military Doctor Testifies under Oath That She Was ORDERED To ‘Cover up’ COVID Vaccine Injuries July 24, 2022
  • Climatic Effect on Marine Biodiversity and their impact on coral reefs July 23, 2022
  • Highlights of India’s first Biotech startup Expo June 13, 2022
  • NTU Singapore scientists develop a ‘fabric’ that turns body movement into electricity June 6, 2022
  • Researchers who jumped into the field from distant disciplines published lower impact work, study finds May 30, 2022
  • Amrita Vishwa Vidyapeetham gets CDSCO nod for clinical trials of first-of-its-kind synthetic jaw-bone graft May 26, 2022
  • AstraZeneca Covid-19 vaccines which uses a chimpanzee adenovirus inked to monkeypox outbreak May 25, 2022
  • Concerns Mount Over COVID-19 ‘Rebounds’ After Treatment With Pfizer’s Paxlovid May 25, 2022
Archives
Categories
  • Articles
  • Articles- Editorials
  • Articles- Guestorials
  • BioControversial
  • BioEvents
  • BioGadgets
  • BioPolicies
  • BioResearch – Academic
  • Biotech News
  • Biotech News – Featured
  • Contents
  • Interviews
  • Interviews – Academia
  • Interviews – Industry
  • SARS- CoV2 & COVID-19 Updates
  • startups
About Us

Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports,  Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology and allied sciences like Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurology, Genetics, Medical Sciences, BioPharma etc.

Call us: _91-9311986177

Email – biotechexpressindia@gmail.com

About Us

About Biotech Express

Advisory and Editorial Board

Contact Us

Policy and Guidelines

Submission policies

Peer review policy    

Copyright policy

 

Follow Us
  • Facebook
  • Twitter
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies. Copyright © 2013-2020 Biotech Express except certain content provided by third parties.

Type above and press Enter to search. Press Esc to cancel.